Inhibition of the JAK/STAT3 pathway has also been shown to produce a similar upregulating effect on CD38 expression, and ruxolitinib suppressed STAT3 activation and enhanced daratumumab‐mediated ADCC in MM cell lines.53 This evidence concerns the gene CD38 and Miyoshi myopathy.